Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00041678 |
Recruitment Status :
Completed
First Posted : July 15, 2002
Last Update Posted : November 11, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Alzheimer Disease | Drug: aripiprazole | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Primary Purpose: | Treatment |
Study Start Date : | January 2000 |
Actual Primary Completion Date : | March 2003 |
Actual Study Completion Date : | March 2003 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 55 Years to 95 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Institutionalized patients with Alzheimer's Disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00041678
United States, California | |
Local Institution | |
Rosemead, California, United States | |
United States, Florida | |
Local Institution | |
Miami, Florida, United States | |
United States, Tennessee | |
Local Institution | |
Nashville, Tennessee, United States | |
United States, Vermont | |
Local Institution | |
Bennington, Vermont, United States | |
Local Institution | |
Burlington, Vermont, United States | |
United States, Wisconsin | |
Local Institution | |
Milwaukee, Wisconsin, United States |
ClinicalTrials.gov Identifier: | NCT00041678 |
Other Study ID Numbers: |
CN138-005 |
First Posted: | July 15, 2002 Key Record Dates |
Last Update Posted: | November 11, 2013 |
Last Verified: | September 2007 |
Psychosis Associated with Dementia of the Alzheimer's Type |
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders Aripiprazole Antidepressive Agents Psychotropic Drugs Antipsychotic Agents Tranquilizing Agents |
Central Nervous System Depressants Physiological Effects of Drugs Dopamine Agonists Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Serotonin 5-HT1 Receptor Agonists Serotonin Receptor Agonists Serotonin Agents Serotonin 5-HT2 Receptor Antagonists Serotonin Antagonists Dopamine D2 Receptor Antagonists Dopamine Antagonists |